secwatch.observer — SEC 8-K summary
======================================

Issuer:     Aditxt, Inc. (ADTX)
CIK:        0001726711
Form:       8-K
Filed at:   2021-12-28T23:59:59+00:00
Accession:  0001213900-21-067652
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.75
Item codes: 1.01, 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Aditxt to acquire AiPharma in all-stock deal valued at ~44.7M shares plus $500K cash
--------------------------------------------------------------------------------

- Initial closing by Jan 31, 2022 for 9.5% of AiPharma: 4.8M shares + $250K cash.
- Secondary closing for remaining 90.5% subject to shareholder and Nasdaq approval: 39.9M shares + $250K cash.
- AiPharma holds exclusive rights to Avigan (favipiravir) for COVID-19; Phase 3 trial missed primary endpoint.
- Two board members, Lauren Chung and Laura Anthony, resigned effective Dec 31, 2021; no disagreement cited.
- AiPharma has strategic alliance with Appili Therapeutics (TSX:APLI) and plans new global clinical trial for Avigan.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1726711/000121390021067652/0001213900-21-067652-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1726711/000121390021067652/ea153046-8k425_aditxtinc.htm
  HTML page:      https://secwatch.observer/filing/0001213900-21-067652

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer